Allergan plc Company Profile (NYSE:ACT)

About Allergan plc (NYSE:ACT)

Allergan plc logoActavis, Inc. formerly Watson Pharmaceuticals, Inc., is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ACT
  • CUSIP: 00507K10
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $297.00
  • 200 Day Moving Avg: $285.00
  • 52 Week Range: $202.00 - $318.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.24
  • P/E Growth: 0
Misc:
  • Average Volume: 2.77 million shs.
 

Frequently Asked Questions for Allergan plc (NYSE:ACT)

What is Allergan plc's stock symbol?

Allergan plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "ACT."

How were Allergan plc's earnings last quarter?

Allergan plc (NYSE:ACT) announced its earnings results on Wednesday, February, 18th. The company reported $3.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.67 by $0.24. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.84 billion. Allergan plc's revenue for the quarter was up 44.2% compared to the same quarter last year. During the same period last year, the firm earned $3.17 earnings per share. View Allergan plc's Earnings History.

Who are some of Allergan plc's key competitors?

How do I buy Allergan plc stock?

Shares of Allergan plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Allergan plc stock cost?

One share of Allergan plc stock can currently be purchased for approximately $299.00.

Analyst Ratings

Consensus Ratings for Allergan plc (NYSE:ACT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Allergan plc (NYSE:ACT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016Leerink SwannBoost Price TargetOutperform$180.00 -> $215.00N/AView Rating Details
11/2/2015Susquehanna Bancshares IncBoost Price TargetPositive$290.00 -> $325.00N/AView Rating Details
6/4/2015Bank of America CorpSet Price TargetBuy$350.00N/AView Rating Details
6/3/2015Raymond James Financial, Inc.Initiated CoverageOutperform$344.00N/AView Rating Details
5/29/2015Deutsche Bank AGBoost Price TargetBuy$336.00 -> $343.00N/AView Rating Details
5/29/2015Canaccord GenuityReiterated RatingBuy$352.00N/AView Rating Details
5/28/2015Citigroup IncInitiated CoverageFocus List -> Focus List$360.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Allergan plc (NYSE:ACT)
Earnings by Quarter for Allergan plc (NYSE:ACT)
Earnings History by Quarter for Allergan plc (NYSE:ACT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Allergan plc (NYSE:ACT)
Current Year EPS Consensus Estimate: $18 EPS
Next Year EPS Consensus Estimate: $21 EPS

Dividends

Dividend History for Allergan plc (NYSE:ACT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Allergan plc (NYSE:ACT)
Insider Trades by Quarter for Allergan plc (NYSE:ACT)
Insider Trades by Quarter for Allergan plc (NYSE:ACT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.00View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.00View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.00View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.64View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.00View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.01View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.00View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.00View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.00View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.00View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.28View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Allergan plc (NYSE:ACT)
Latest Headlines for Allergan plc (NYSE:ACT)
Source:
DateHeadline
prnewswire.com logoAllergan Announces Commencement of Proposed Public Offering of Senior Notes to Refinance Existing Debt - PR Newswire (press release)
www.prnewswire.com - May 23 at 5:44 AM
prnewswire.com logoAllergan to Present at the Bernstein Strategic Decisions Conference - PR Newswire (press release)
www.prnewswire.com - May 15 at 3:18 PM
finance.yahoo.com logoTeva Q1 profit tops estimates, revenue up on Actavis deal
finance.yahoo.com - May 11 at 3:31 PM
prnewswire.com logoAllergan Announces Proposed Public Offering of Senior Notes to Refinance Existing Debt - PR Newswire (press release)
www.prnewswire.com - May 10 at 9:34 AM
prnewswire.com logoAllergan to Present at the Bank of America Merrill Lynch Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - May 4 at 3:20 PM
americanbankingnews.com logoAllergan plc (ACT) Receiving Somewhat Negative Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 10:37 AM
finance.yahoo.com logoAllergan to Present New and Updated Linzess®, Viberzi®, Relamorelin, Linaclotide Delayed Release, and Cenicriviroc ... - Yahoo Finance
finance.yahoo.com - May 1 at 9:49 AM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Impact Allergan plc (ACT) Stock Price
www.americanbankingnews.com - April 29 at 8:46 AM
prnewswire.com logoAllergan Successfully Completes ZELTIQ® Aesthetics Acquisition - PR Newswire (press release)
www.prnewswire.com - April 28 at 3:31 PM
prnewswire.com logoAllergan Announces Advisory Role for Breast Implant Pioneer Hani Zeini
www.prnewswire.com - April 27 at 11:29 AM
prnewswire.com logoAllergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device ... - PR Newswire (press release)
www.prnewswire.com - April 25 at 3:17 PM
prnewswire.com logoAllergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and ... - PR Newswire (press release)
www.prnewswire.com - April 20 at 8:35 PM
prnewswire.com logoAllergan Partners with TARGET PharmaSolutions to Advance NASH Research - PR Newswire (press release)
www.prnewswire.com - April 20 at 3:18 PM
americanbankingnews.com logoAllergan plc (ACT) Given Daily Media Impact Rating of -0.18
www.americanbankingnews.com - April 19 at 7:42 AM
prnewswire.com logoAllergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration - PR Newswire (press release)
www.prnewswire.com - April 18 at 5:58 AM
americanbankingnews.com logoAllergan plc (ACT) Receiving Somewhat Negative News Coverage, Study Shows
www.americanbankingnews.com - April 15 at 8:44 AM
finance.yahoo.com logoAllergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer ... - Yahoo Finance
finance.yahoo.com - April 13 at 3:33 PM
prnewswire.com logoAllergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common - PR Newswire (press release)
www.prnewswire.com - April 11 at 8:27 AM
prnewswire.com logoAllergan Receives 2017 ENERGY STAR® Partner of the Year - Sustained Excellence Award from U.S. Environmental ... - PR Newswire (press release)
www.prnewswire.com - April 11 at 8:27 AM
prnewswire.com logoAllergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk - PR Newswire (press release)
www.prnewswire.com - April 9 at 6:02 AM
prnewswire.com logoAllergan Reports Topline Phase II Data Supporting Advancement of BOTOX® (onabotulinumtoxinA) for the Treatment ... - PR Newswire (press release)
www.prnewswire.com - April 7 at 6:01 AM
prnewswire.com logoAllergan to Report First Quarter 2017 Earnings and Host Conference Call and Webcast - PR Newswire (press release)
www.prnewswire.com - April 7 at 6:01 AM
prnewswire.com logoAllergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy - PR Newswire (press release)
www.prnewswire.com - April 7 at 6:01 AM
prnewswire.com logoAllergan and ZELTIQ Announce Expiration of Hart-Scott-Rodino Waiting Period for Pending Transaction - PR Newswire (press release)
www.prnewswire.com - April 7 at 6:01 AM
prnewswire.com logoaTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors - PR Newswire (press release)
www.prnewswire.com - April 3 at 3:27 PM
investorplace.com logoWhy Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Risky - Investorplace.com
investorplace.com - April 3 at 3:27 PM
bizjournals.com logoUnited Therapeutics loses challenge to its drug patent
www.bizjournals.com - April 3 at 3:27 PM
globenewswire.com logoAllergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate ... - GlobeNewswire (press release)
globenewswire.com - March 29 at 8:26 PM
finance.yahoo.com logoAllergan and Paratek Announce Positive Results From Two Phase 3 ... - Yahoo Finance
finance.yahoo.com - March 28 at 7:49 AM
prnewswire.com logoAllergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate ... - PR Newswire (press release)
www.prnewswire.com - March 27 at 3:29 PM
streetinsider.com logoPre-Open Movers 03/14: (MGI) (RT) (ETRM) Higher; (ANTH) (AUPH) (VRX) Lower (more...) - StreetInsider.com
www.streetinsider.com - March 14 at 8:21 PM
finance.yahoo.com logoAward Winning Actor And Hip-Hop Artist Common Joins Allergan's See America(SM) Initiative To Further The Fight ... - Yahoo Finance
finance.yahoo.com - March 14 at 8:21 PM
finance.yahoo.com logoNew Survey Reveals Impact Of Double Chin On Self-Perception And Behavior
finance.yahoo.com - March 14 at 3:18 PM
globenewswire.com logoAllergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 8:19 AM
reuters.com logoTrump poised to nominate Scott Gottlieb to head FDA: sources
www.reuters.com - March 11 at 1:21 AM
huffingtonpost.com logoDonald Trump Poised To Nominate Scott Gottlieb To Head FDA: Reports
www.huffingtonpost.com - March 10 at 8:19 PM
finance.yahoo.com logoFDA Accepts Supplemental New Drug Application (sNDA) For ... - Yahoo Finance
finance.yahoo.com - March 8 at 3:19 PM
finance.yahoo.com logoZELTIQ Announces Fourth Quarter and Full Year 2016 Financial Results - Yahoo Finance
finance.yahoo.com - March 2 at 3:22 PM
finance.yahoo.com logoAllergan to Present at the Barclays Global Healthcare Conference - Yahoo Finance
finance.yahoo.com - March 2 at 3:22 PM
forbes.com logoThe Best Dividend Investors Are Preparing For Higher Interest Rates
www.forbes.com - March 2 at 3:22 PM
prnewswire.com logoLisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan - PR Newswire (press release)
www.prnewswire.com - February 28 at 7:47 AM
finance.yahoo.com logoAllergan to Present at Cowen and Company 37th Annual Health Care Conference - Yahoo Finance
finance.yahoo.com - February 28 at 7:47 AM
finance.yahoo.com logoAllergan's New Eyepowerment™ Campaign Urges The Up To 33 Million Americans Suffering from Symptoms of ... - Yahoo Finance
finance.yahoo.com - February 27 at 3:28 PM
finance.yahoo.com logoLisa DeFrancesco, Vice President of Investor Relations, to Leave Allergan - Yahoo Finance
finance.yahoo.com - February 27 at 3:28 PM
finance.yahoo.com logoTop Research Reports for February 24, 2017
finance.yahoo.com - February 24 at 3:16 PM
bloomberg.com logoAllergan CEO Pushes for Trump to Lead Drug Price Discussions
www.bloomberg.com - February 23 at 3:19 PM
prnewswire.com logoAllergan to Sponsor Alzheimer's Foundation of America '15th Anniversary National Educating America' Tour - PR Newswire (press release)
www.prnewswire.com - February 23 at 1:21 AM
nasdaq.com logoAssembly Biosciences Announces the Closing and Early ... - Nasdaq - Nasdaq
www.nasdaq.com - February 21 at 3:35 PM
ft.com logo[$$] Big pharma bets billions on 'silent' liver disease
www.ft.com - February 21 at 5:46 AM
investopedia.com logoRoche Sues Amgen Over Avastin Biosimilar (AMGN)
www.investopedia.com - February 20 at 3:18 PM

Social

Allergan plc (ACT) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff